Crohn’s Disease & Ulcerative Colitis are each a type of Inflammatory Bowel Disease (IBD). Heredity is believed to be a factor in developing IBD. Studies show that 5% to 20% of those affected have a close relative (parent, child, or sibling) with CD or UC, though the risk is higher with Crohn’s.
They can also be progressive health conditions, meaning that symptoms like gut pain, diarrhea and fatigue can—if not properly managed—get worse.
Lastly, Crohn’s & Ulcerative Colitis are what’s called “autoimmune” diseases. This means the body’s immune system attacks healthy tissue—in this case, different parts of the GI tract—by mistake. Fortunately, treatments exist, but more options are needed.
People may not give much thought to clinical research, but everything from aspirin to chemotherapy has been carefully tested before being prescribed by your doctor.
Clinical trials need human volunteers, who participate under the supervision of a doctor and/or health professionals. As the trial goes on, the doctors gather more and more information about the drug or treatment under investigation. It is only through clinical trials that we learn if drugs and treatments are both effective and safe.
For the safety of both staff and patients, Synexus sites are COVID-19 SMART facilities. That means we use best practices to reduce virus exposure and are dedicated to ensuring we remain open and available for the research of investigational medications.
Dedicated to conducting clinical trials, Synexus has been investigating the effectiveness of new medicines and treatments for more than 25 years. We have vast experience in conducting clinical research with over 180 sites around the world. Each site has its own dedicated team of highly trained doctors and nurses to provide our patients with the highest level of comfort and professionalism.
More about Synexus